ALI/ARDS Clinical Sub-phenotyping Study

Sponsor
China-Japan Friendship Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06123962
Collaborator
(none)
1,500
24.4

Study Details

Study Description

Brief Summary

  1. Construct a structured clinical data and biosample information platform for Chinese patients with acute lung injury/ acute respiratory distress syndrome.

  2. By deciphering the heterogeneity of patients with acute lung injury/ acute respiratory distress syndrome, achieve clinical, longitudinal physiological, and biological sub-phenotyping to guide individualized precision treatment and improve prognosis.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Collect peripheral blood and bronchoalveolar lavage fluid

Detailed Description

Acute lung injury/ acute respiratory distress syndrome is one of the most common and complex critical illnesses in clinical practice, with a high mortality rate of 45% to 50%. Currently, effective therapeutic strategies for this condition are still lacking. Increasing evidence suggests that the significant heterogeneity of this disease plays a crucial role in the poor treatment outcomes and high mortality rates observed in patients. Therefore, this study aims to analyze the heterogeneity of acute lung injury/ acute respiratory distress syndrome patients and establish a clinical classification system for acute lung and extrapulmonary organ injuries.

The objectives of this study include establishing a nationwide clinical database and biobank for acute lung injury / acute respiratory distress syndrome by collecting clinical data and biological samples from various provinces. By overcoming the barriers posed by diverse and heterogeneous data sources, mathematical and machine learning models will be utilized to construct clinical, physiological, and biological classification systems for acute lung and extrapulmonary organ injuries. The proposed classification model will be validated multiple times using international public databases and prospective acute lung injury/acute respiratory distress syndrome cohorts to ensure its stability and generalizability. The mapping relationship between different classifications and patient prognosis as well as treatment responsiveness will be explored.

Moreover, a machine learning-based supervised technique will be applied to develop a bedside simplified model (Point-of-Care model) and establish a bedside clinical classification decision system. Ultimately, this research aims to provide a foundation for standardized and precision-guided clinical diagnostic and therapeutic pathways, promoting improved treatment outcomes and overall prognosis in acute lung injury/ acute respiratory distress syndrome.

Study Design

Study Type:
Observational
Anticipated Enrollment :
1500 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Acute Lung/ Acute Respiratory Distress Syndrome and Extra-pulmonary Organ Injury Clinical Sub-phenotyping Study
Anticipated Study Start Date :
Dec 20, 2023
Anticipated Primary Completion Date :
Dec 31, 2025
Anticipated Study Completion Date :
Dec 31, 2025

Outcome Measures

Primary Outcome Measures

  1. ICU mortality [up to 12 weeks]

    In ICU mortality

  2. hospital mortality [up to 24 weeks]

    In hospital mortality

Secondary Outcome Measures

  1. 28 days without mechanical ventilation [up to 28 days]

    28 days without mechanical ventilation

  2. length of stay in the ICU [up to 12 weeks]

    length of stay in the ICU

  3. Total length of hospital stay [up to 24 weeks]

    Total length of hospital stay

  4. Mortality at 1 year after discharge [through study completion, an average of 1 year]

    Mortality at 1 year after discharge

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Meet the diagnostic criteria for Acute Respiratory Distress Syndrome (ARDS) according to the updated global definition in 2023.

  • The patient or their legal representative signs an informed consent form.

Exclusion Criteria:
  • Individuals aged less than 18 years old.

  • Those who refuse to participate in the study.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • China-Japan Friendship Hospital

Investigators

  • Study Director: Jingen Xia, China-Japan Friendship Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Jingen Xia, Clinical Professor, China-Japan Friendship Hospital
ClinicalTrials.gov Identifier:
NCT06123962
Other Study ID Numbers:
  • 2022YFC2504401
First Posted:
Nov 9, 2023
Last Update Posted:
Nov 9, 2023
Last Verified:
Nov 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Jingen Xia, Clinical Professor, China-Japan Friendship Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 9, 2023